It is demonstrably overexpressed in >70% of NSCLC (Richardson and Johnson, 1993), with overt Myc gene amplification in the ∼20% of tumors with poorest prognosis (Iwakawa et al., 2011, Seo et al., 2014, Wolfer et al., 2010). This evidence concerns the gene MYC and non-small cell lung carcinoma.